Department of Gastrointestinal Surgery, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, People's Republic of China.
Department of Clinical Medicine, Fujian Medical University, Fuzhou, Fujian, People's Republic of China.
Technol Cancer Res Treat. 2021 Jan-Dec;20:1533033820986826. doi: 10.1177/1533033820986826.
has different roles in multiple types of cancers and participates in various molecular mechanisms. However, the prognostic value of in patients with hepatocellular carcinoma (HCC) still remains unclear. We carried the study to evaluate the prognostic value and identified underlying molecular mechanisms in HCC.
Firstly, the association of expression and clinicopathological parameters was evaluated by in GSE14520. Next, expression in HCC was performed using GSE14520, GSE36376, GSE76427 and The Cancer Genome Atlas (TCGA) profile. Furthermore, Kaplan-Meier analysis, Univariate and Multivariate Cox regression analysis, subgroup analysis was performed to evaluate the prognostic value in HCC. Finally, GO enrichment analysis, gene set enrichment analysis (GSEA) and weighted gene co-expression network analysis (WGCNA) were performed to revealed underlying molecular mechanisms.
The expression of was positively correlated with the development of HCC. Next, high expression was significantly associated with poorer survival (all < 0.05) and the impact of on all overall survival (OS), disease-free survival (DFS), relapse-free survival (RFS), disease specific survival (DSS) and progression free interval (PFI) was specific for HCC among other 29 cancer types. Subgroup analysis showed that overexpression was significantly associated with poorer OS in patients with HCC. Finally, might participate in the status conversion from metabolic-dominant to extracellular matrix-dominant, and the activation of ECM-related biological process might contribute to high higher mortality risk for patients with HCC.
may play an important role in the progression of HCC, and may be considered as a novel and effective biomarker for predicting prognosis for patients with HCC.
在多种癌症中具有不同的作用,并参与各种分子机制。然而, 在肝细胞癌(HCC)患者中的预后价值仍不清楚。我们进行了这项研究,以评估其在 HCC 中的预后价值和潜在的分子机制。
首先,通过 GSE14520 评估 表达与临床病理参数的相关性。接下来,使用 GSE14520、GSE36376、GSE76427 和癌症基因组图谱(TCGA)图谱进行 HCC 中的 表达分析。此外,进行 Kaplan-Meier 分析、单因素和多因素 Cox 回归分析、亚组分析,以评估 在 HCC 中的预后价值。最后,进行 GO 富集分析、基因集富集分析(GSEA)和加权基因共表达网络分析(WGCNA),以揭示潜在的分子机制。
的表达与 HCC 的发生呈正相关。接下来,高 表达与较差的生存显著相关(均<0.05),并且 对所有总生存期(OS)、无病生存期(DFS)、无复发生存期(RFS)、疾病特异性生存期(DSS)和无进展生存期(PFI)的影响在其他 29 种癌症类型中对 HCC 是特异的。亚组分析表明, 在 HCC 患者中,高表达与 OS 较差显著相关。最后, 可能参与从代谢优势到细胞外基质优势的状态转换,ECM 相关生物学过程的激活可能导致 HCC 患者的高死亡率风险增加。
可能在 HCC 的进展中发挥重要作用,并且可以被视为预测 HCC 患者预后的新型有效生物标志物。